Clinical Trials

No Picture
Clinical Trials

Human Interferon α1b Inhalation Solution Against Respiratory Syncytial Virus in Children With Lower Respiratory Tract Infections

May 29, 2026

ClinicalTrials.gov ID NCT06363370 Sponsor Kexing Biopharm Co., Ltd. Information provided by Kexing Biopharm Co., Ltd. (Responsible Party) Last Update Posted 2024-04-12 Brief Summary To evaluate the efficacy and safety of interferon α1b (GB05) in the treatment of children under 2 years of age with respiratory syncytial virus infection. Detailed Description [READ MORE]

No Picture
Clinical Trials

Efficacy and Safety of Antiviral Therapy With Peg-interferon for Chronic Hepatitis B Complicated With Nonalcoholic Fatty Liver Disease（OCEAN PROJECT）

May 29, 2026

ClinicalTrials.gov ID NCT06368882 Sponsor First Affiliated Hospital of Wenzhou Medical University Information provided by First Affiliated Hospital of Wenzhou Medical University (Responsible Party) Last Update Posted 2024-04-16 Brief Summary This is a prospective, multicenter, open-label, non-randomized controlled real-world study to explore the efficacy and safety and to accumulate more evidence-based [READ MORE]

No Picture
Clinical Trials

[68Ga]Ga-Sa-DABI-4 PET Imaging of Stimulator of Interferon Gene Expression in Cancer Patients

May 29, 2026

ClinicalTrials.gov ID NCT06419361 Sponsor First Affiliated Hospital of Chongqing Medical University Information provided by Xiaoyang Zhang, First Affiliated Hospital of Chongqing Medical University (Responsible Party) Last Update Posted 2025-06-04 Brief Summary Stimulator of interferon gene (STING) protein plays a vital role in the immune surveillance of tumor microenvironment. Monitoring STING [READ MORE]

No Picture
Clinical Trials

Evaluate the Efficacy and Safety of Interferon-α Combined With ATO in the Treatment of Arsenic-resistant APL (APL)

March 30, 2026

Evaluate the Efficacy and Safety of Interferon-α Combined With ATO in the Treatment of Arsenic-resistant APL (APL) ClinicalTrials.gov ID NCT06450145 Sponsor Zhejiang Provincial People’s Hospital Information provided by Zhejiang Provincial People’s Hospital (Responsible Party Brief Summary This study was a single-arm, open study. After the screening period, arsenic-resistant APL patients [READ MORE]

Clinical Trials

Interferon-α for TP53 Myeloid Malignancy Post Allo-HSCT

March 30, 2026

Interferon-α for TP53 Myeloid Malignancy Post Allo-HSCT ClinicalTrials.gov ID NCT06130579 Sponsor Peking University People’s Hospital Information provided by Xiao-Jun Huang, Peking University People’s Hospital (Responsible Party) Last Update Posted 2025-06-03 Brief Summary To investigate the efficacy of interferon-α prophylaxis in patients with acute myeloid leukemia (AML) and myelodysplastic syndrome (MDS) [READ MORE]

Clinical Trials

Interferon-gamma as Adjunctive Therapy in Chronic Pulmonary Aspergillosis: a Randomised Feasibility Study (INCAS)

March 30, 2026

Interferon-gamma as Adjunctive Therapy in Chronic Pulmonary Aspergillosis: a Randomised Feasibility Study (INCAS) ClinicalTrials.gov ID NCT05653193 Sponsor Manchester University NHS Foundation Trust Information provided by Manchester University NHS Foundation Trust (Responsible Party) Last Update Posted 2025-03-03 Brief Summary This study explores the role of treatment with interferon-gamma to improve outcomes [READ MORE]

Clinical Trials

Concentrations of Pro-inflammatory and Anti-inflammatory Cytokines and Metallopeptidases in the Serum During the Treatment of Pain Caused by Bulging of the Intervertebral Disc in the Lumbar Spine

March 1, 2026

Concentrations of Pro-inflammatory and Anti-inflammatory Cytokines and Metallopeptidases in the Serum During the Treatment of Pain Caused by Bulging of the Intervertebral Disc in the Lumbar Spine ClinicalTrials.gov ID NCT06545812 Sponsor: Josip Juraj Strossmayer, University of Osijek Information provided: by Karla Rožac, Josip Juraj Strossmayer, University of Osijek (Responsible Party) [READ MORE]

Clinical Trials

A Single-arm, Dose-escalation Trial of Long-acting Recombinant Human IL-7 (NT-I7, Efineptakin Alfa) for Idiopathic CD4 Lymphopenia

March 1, 2026

A Single-arm, Dose-escalation Trial of Long-acting Recombinant Human IL-7 (NT-I7, Efineptakin Alfa) for Idiopathic CD4 Lymphopenia ClinicalTrials.gov ID NCT05600920 Sponsor: National Institute of Allergy and Infectious Diseases (NIAID) Information provided by: National Institutes of Health Clinical Center (CC) (National Institute of Allergy and Infectious Diseases (NIAID)) (Responsible Party) Last Update [READ MORE]

Clinical Trials

Immune Infiltrate Analysis of Psoriasis Skin During Therapy With Anti-interleukin 23 (IL-23)

March 1, 2026

Immune Infiltrate Analysis of Psoriasis Skin During Therapy With Anti-interleukin 23 (IL-23) ClinicalTrials.gov ID NCT06792487 Sponsor: Fondazione Policlinico Universitario Agostino Gemelli IRCCS Information provided by: Fondazione Policlinico Universitario Agostino Gemelli IRCCS (Responsible Party) Last Update Posted: 2025-01-24 Brief Summary Psoriasis is an immune-mediated inflammatory skin disease characterized by the presence [READ MORE]

No Picture
Clinical Trials

Comparison Between Interleukin 6 and Procalcitonin in Detecting Sepsis and Incidence of Mortality in Burn ICU Patients

February 2, 2026

ClinicalTrials.gov ID NCT06915974 Sponsor Ain Shams University Information provided by Ain Shams University (Responsible Party) Last Update Posted 2025-04-08 Brief Summary The investigators will compare the efficacy of Interleukin-6 (IL-6) as a better indicator than procalcitonin in burn patients with sepsis or septic shock regarding success of treatment and early [READ MORE]